Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 364,252 | 311,337 | 321,083 | 287,268 | 212,802 |
| Cost of Goods | 40,007 | 26,847 | 24,448 | 18,122 | 9,065 |
| Gross Profit | 324,245 | 284,490 | 296,635 | 269,146 | 203,737 |
| Operating Expenses | 380,560 | 378,060 | 356,692 | 383,243 | 251,004 |
| Operating Income | -56,308 | -92,723 | -59,609 | -113,975 | -47,202 |
| Interest Expense | 7,940 | 7,819 | 8,297 | 7,451 | 3,264 |
| Other Income | 6,309 | 6,151 | 9,331 | 7,236 | 8,185 |
| Pre-tax Income | -57,939 | -94,391 | -58,575 | -114,190 | -42,281 |
| Net Income Continuous | -57,939 | -94,391 | -58,575 | -114,190 | -42,281 |
| Net Income | $-57,939 | $-94,391 | $-58,575 | $-114,190 | $-42,281 |
| EPS Basic Total Ops | -1.99 | -3.25 | -3.66 | -5.08 | -1.50 |
| EPS Basic Continuous Ops | -1.99 | -3.25 | -3.67 | -5.08 | -1.50 |
| EPS Diluted Total Ops | -1.99 | -3.25 | -3.66 | -5.08 | -1.50 |
| EPS Diluted Continuous Ops | -1.99 | -3.25 | -3.67 | -5.08 | -1.50 |
| EPS Diluted Before Non-Recurring Items | -1.99 | -3.25 | -2.57 | -5.08 | -1.90 |
| EBITDA(a) | $-54,818 | $-91,480 | $-57,201 | $-111,737 | $-46,399 |